Pfizer (NYSE:PFE) gained EU antitrust approval for its $43 billion acquisition of Seagen, a cancer drug maker. This acquisition, announced in March, is Pfizer's largest recent purchase, fueled by the financial success of its COVID-19 vaccines and treatments. The European Commission found no significant competition or pricing concerns in the 27-country European...
Read about company because it earns alot of money. They produce gloves. Maybe this is the moment to buy... we will see. Great Risk Reward ratio as fundamentaly this company should be priced PLN 1500
